(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 December 2016 (22.12.2016)

WIPO | PCT

(10) International Publication Number
WO 2016/203239 A1

(51) International Patent Classification:
A61K 45/06 (2006.01) *A61K 36/185* (2006.01)
A61K 31/352 (2006.01) *A61P 25/08* (2006.01)

(21) International Application Number:
PCT/GB2016/051792

(22) International Filing Date:
16 June 2016 (16.06.2016)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1510664.4 17 June 2015 (17.06.2015) GB

(71) Applicant: **GW RESEARCH LIMITED** [GB/GB]; Sovereign House, Vision Park, Chivers Way, Histon, Cambridge Cambridgeshire CB24 9BZ (GB).

(72) Inventors: **GUY, Geoffrey**; c/o GW Pharma Limited, Sovereign House, Vision Park, Chivers Way, Histon, Histon, Cambridge Cambridgeshire CB24 9BZ (GB). **WRIGHT, Stephen**; c/o GW Pharma Limited, Sovereign House, Vision Park, Chivers Way, Histon, Cambridge Cambridgeshire CB24 9BZ (GB). **MEAD, Alice**; c/o GW Pharma Limited, Sovereign House, Vision Park, Chivers Way, Histon Cambridge Cambridgeshire CB24 9BZ (GB). **CHEETHAM, Emma**; c/o GW Pharma Limited, Sovereign House, Vision Park, Chivers Way, Histon, Cambridge Cambridgeshire CB24 9BZ (GB). **DEVINSKY, Orrin**; c/o Department of Neurology, NYU Comprehensive Epilepsy Center, 223 East 34th Street, New York, New York 10016 (US). **SCHILLER, Dominic**; c/o Equipped 4 (IP) Limited, 47 Hamilton Square, Birkenhead Merseyside CH41 5AR (GB).

(74) Agent: **HGF LIMITED**; 4th Floor, Merchant Exchange, 17-19 Whitworth Street West, Manchester Greater Manchester M1 5WG (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

(54) Title: USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY

Figure 1. ILAE Proposal for Revised Terminology for Organisation of Seizures and Epilepsies 2010



(57) Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of focal seizures. In one embodiment the patients suffering from focal seizures are children and young adults. CBD appears particularly effective in reducing focal seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKL5; Neuronal ceroid lipofuscinoses(NCL); febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities in comparison to other seizure types. Significantly CBD additionally is very effective in the reduction of a sub-type of focal seizures, focal seizures with impairment.

WO 2016/203239 A1

USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY

FIELD OF THE INVENTION

[0001] The present invention relates to the use of cannabidiol (CBD) in the treatment of focal seizures. In one embodiment the patients suffering from focal seizures are children and young adults. CBD appears particularly effective in reducing focal seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKL5; Neuronal ceroid lipofuscinoses (NCL); febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities in comparison to other seizure types.

[0002] Significantly CBD additionally is very effective in the reduction of a sub-type of focal seizures, focal seizures with impairment. The etiologies of patients which suffer from focal seizures with impairment include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKL5; febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities.

[0003] In these patients treatment with CBD reduced the occurrence of absence seizures or myoclonic absence seizures by greater than 50% in a large proportion of patients, 64% and 75% respectively. This was surprising given that the proportion of patients benefitting from a greater than 50% reduction in total seizures was significantly less, (46%), in all subjects treated.

[0004] Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

[0005] In use the CBD may be used concomitantly with one or more other anti-epileptic drugs (AED). Alternatively the CBD may be formulated for administration separately, sequentially or simultaneously with one or more AED or the combination may be provided in a single dosage form. Where the CBD is formulated for administration separately, sequentially or simultaneously it may be provided as a kit or together with instructions to administer the one or more components in the manner indicated. It may also be used as the sole medication, i.e. as a monotherapy.

BACKGROUND TO THE INVENTION

[0006] Epilepsy occurs in approximately 1% of the population worldwide, (Thurman *et al.*, 2011) of which 70% are able to adequately control their symptoms with the available existing anti-epileptic drugs (AED). However, 30% of this patient group, (Eadie *et al.*, 2012), are unable to obtain seizure freedom using the AED that are available and as such are termed as suffering from intractable or "treatment-resistant epilepsy" (TRE).

[0007] Intractable or treatment-resistant epilepsy was defined in 2009 by the International League Against Epilepsy (ILAE) as "*failure of adequate trials of two tolerated and appropriately chosen and used AED schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom*" (Kwan *et al.*, 2009).

[0008] Individuals who develop epilepsy during the first few years of life are often difficult to treat and as such are often termed treatment-resistant. Children who undergo frequent seizures in childhood are often left with neurological damage which can cause cognitive, behavioral and motor delays.

[0009] Childhood epilepsy is a relatively common neurological disorder in children and young adults with a prevalence of approximately 700 per 100,000. This is twice the number of epileptic adults per population.

[0010] When a child or young adult presents with a seizure, investigations are normally undertaken in order to investigate the cause. Childhood epilepsy can be caused by many different syndromes and genetic mutations and as such diagnosis for these children may take some time.

[0011] The main symptom of epilepsy is repeated seizures. In order to determine the type of epilepsy or the epileptic syndrome that a patient is suffering from, an investigation into the type of seizures that the patient is experiencing is undertaken. Clinical observations and electroencephalography (EEG) tests are conducted and the type(s) of seizures are classified according to the ILAE classification described below and in Figure 1.

[0012] The International classification of seizure types proposed by the ILAE was adopted in 1981 and a revised proposal was published by the ILAE in 2010 and has not yet superseded the 1981 classification. Figure 1 is adapted from the 2010 proposal for revised terminology and includes the proposed changes to replace the terminology of partial with focal. In addition the term "simple partial seizure" has been replaced by the term "focal seizure where awareness / responsiveness is not impaired" and the term "complex partial seizure" has been replaced by the term "focal seizure where awareness / consciousness is impaired".

[0013] From Figure 1 it can be seen that Generalised seizures, where the seizure arises within and rapidly engages bilaterally distributed networks, can be split into six subtypes: Tonic-

Clonic (grand mal) seizures; Absence (petit mal) Seizures; Clonic Seizures; Tonic Seizures; Atonic Seizures and Myoclonic Seizures.

[0014] Focal (partial) seizures where the seizure originates within networks limited to only one hemisphere, are also split into sub-categories. Here the seizure is characterized according to one or more features of the seizure, including aura, motor, autonomic and awareness / responsiveness. Where a seizure begins as a localized seizure and rapidly evolves to be distributed within bilateral networks this seizure is known as a Bilateral convulsive seizure, which is the proposed terminology to replace Secondary Generalized Seizures (generalized seizures that have evolved from focal seizures and are no longer remain localized).

[0015] Focal seizures where the subjects awareness / responsiveness is altered are referred to as focal seizures with impairment and focal seizures where the awareness or responsiveness of the subject is not impaired are referred to as focal seizures without impairment.

[0016] Focal seizures may occur in epilepsy syndromes including: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKL5; Neuronal ceroid lipofuscinoses (NCL); febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities.

[0017] Epileptic syndromes often present with many different types of seizure and identifying the types of seizure that a patient is suffering from is important as many of the standard AED's are targeted to treat or are only effective against a given seizure type / sub-type.

[0018] One such childhood epilepsy is Dravet syndrome. Onset of Dravet syndrome almost always occurs during the first year of life with clonic and tonic-clonic seizures in previously healthy and developmentally normal infants (Dravet, 2011). Symptoms peak at about five months of age. Other seizures develop between one and four years of age such as prolonged focal dyscognitive seizures and brief absence seizures.

[0019] In diagnosing Dravet syndrome both focal and generalised seizures are considered to be mandatory, Dravet patients may also experience atypical absence seizures, myoclonic absence seizures, atonic seizures and non-convulsive status epilepticus.

[0020] Seizures progress to be frequent and treatment-resistant, meaning that the seizures do not respond well to treatment. They also tend to be prolonged, lasting more than 5 minutes. Prolonged seizures may lead to status epilepticus, which is a seizure that lasts more than 30 minutes, or seizures that occur in clusters, one after another.

[0021] Prognosis is poor and approximately 14% of children die during a seizure, because of infection, or suddenly due to uncertain causes, often because of the relentless neurological decline. Patients develop intellectual disability and life-long ongoing seizures. Intellectual

impairment varies from severe in 50% patients, to moderate and mild intellectual disability each accounting for 25% of cases.

[0022] There are currently no FDA approved treatments specifically indicated for Dravet syndrome. The standard of care usually involves a combination of the following anticonvulsants: clobazam, clonazepam, levetiracetam, topiramate and valproic acid.

[0023] Stiripentol is approved in Europe for the treatment of Dravet syndrome in conjunction with clobazam and valproic acid. In the US, stiripentol was granted an Orphan Designation for the treatment of Dravet syndrome in 2008; however, the drug is not FDA approved.

[0024] Potent sodium channel blockers used to treat epilepsy actually increase seizure frequency in patients with Dravet Syndrome. The most common are phenytoin, carbamazepine, lamotrigine and rufinamide.

[0025] Management may also include a ketogenic diet, and physical and vagus nerve stimulation. In addition to anti-convulsive drugs, many patients with Dravet syndrome are treated with anti-psychotic drugs, stimulants, and drugs to treat insomnia.

[0026] The first line treatment for focal seizures are AED such as carbamezapine or lamotrigine. Levetiracetam, oxycarbamezapine or sodium valproate are also considered to be of use. A combination of these medicaments may be required in order to treat focal seizures.

[0027] Common AED defined by their mechanisms of action are described in the following tables:

[0028] **Table 1. Examples of narrow spectrum AED**

Narrow-spectrum AED	Mechanism	Indication
Phenytoin	Sodium channel	Complex partial Tonic-clonic
Phenobarbital	GABA / Calcium channel	Partial seizures Tonic-clonic
Carbamazepine	Sodium channel	Partial seizures Tonic-clonic Mixed seizures
Oxcarbazepine	Sodium channel	Partial seizures Tonic-clonic Mixed seizures
Gabapentin	Calcium channel	Partial seizures Mixed seizures

Pregabalin	Calcium channel	Adjunct therapy for partial seizures with or without secondary generalisation
Lacosamide	Sodium channel	Adjunct therapy for partial seizures
Vigabatrin	GABA	Secondarily generalized tonic-clonic seizures Partial seizures Infantile spasms due to West syndrome

[0029] Table 2. Examples of broad spectrum AED

Broad-spectrum AED	**Mechanism**	**Indication**
Valproic acid	GABA / Sodium channel	First-line treatment for tonic-clonic seizures, absence seizures and myoclonic seizures Second-line treatment for partial seizures and infantile spasms. Intravenous use in status epilepticus
Lamotrigine	Sodium channel	Partial seizures Tonic-clonic Seizures associated with Lennox-Gastaut syndrome
Ethosuximide	Calcium channel	Absence seizures
Topiramate	GABA / Sodium channel	Seizures associated with Lennox-Gastaut syndrome
Zonisamide	GABA / Calcium /Sodium channel	Adjunctive therapy in adults with partial-onset seizures Infantile spasm

		Mixed seizure Lennox-Gastaut syndrome Myoclonic Generalised tonic-clonic seizure
Levetiracetam	Calcium channel	Partial seizures Adjunctive therapy for partial, myoclonic and tonic-clonic seizures
Clonazepam	GABA	Typical and atypical absences Infantile myoclonic Myoclonic seizures Akinetic seizures
Rufinamide	Sodium channel	Adjunctive treatment of partial seizures associated with Lennox-Gastaut syndrome

[0030] Table 3. Examples of AED used specifically in childhood epilepsy

AED	Mechanism	Indication
Clobazam	GABA	Adjunctive therapy in complex partial seizures Status epilepticus Myoclonic Myoclonic-absent Simple partial Complex partial Absence seizures Lennox-Gastaut syndrome
Stiripentol	GABA	Severe myoclonic epilepsy in infancy (Dravet syndrome)

[0031] From these tables it can be seen that there are many AED are approved for use in focal (partial) seizures which work by a different mechanisms. Indeed the only AED that has

been approved for use in the treatment of complex partial seizures (focal seizures with impairment) is the AED phenytoin.

[0032] Over the past forty years there have been a number of animal studies on the use of the non-psychoactive cannabinoid cannabidiol (CBD) to treat seizures. For example, Consroe *et al.*, (1982) determined that CBD was able to prevent seizures in mice after administration of pro-convulsant drugs or an electric current.

[0033] Studies in epileptic adults have also occurred in the past forty years with CBD. Cunha *et al.* reported that administration of CBD to eight adult patients with generalized epilepsy resulted in a marked reduction of seizures in 4 of the patients (Cunha *et al.*, 1980).

[0034] A study in 1978 provided 200 mg/day of pure CBD to four adult patients, two of the four patients became seizure free, whereas in the remainder seizure frequency was unchanged (Mechoulam and Carlini, 1978).

[0035] In contrast to the studies described above, an open label study reported that 200 mg / day of pure CBD was ineffective in controlling seizures in twelve institutionalized adult patients (Ames and Cridland, 1986).

[0036] Based on the fact that chronologically the last study to look at the effectiveness of CBD in patients with epilepsy proved that CBD was unable to control seizures, there would be no expectation that CBD might be useful as an anti-convulsant agent.

[0037] In the past forty years of research there have been over thirty drugs approved for the treatment of epilepsy none of which are cannabinoids. Indeed, there appears to have been a prejudice against cannabinoids, possibly due to the scheduled nature of these compounds and / or the fact that THC, which is a known psychoactive, has been ascribed as a pro-convulsant (Consroe *et al.*, 1977).

[0038] A paper published recently suggested that cannabidiol-enriched cannabis may be efficacious in the treatment of epilepsy. Porter and Jacobson (2013) report on a parent survey conducted via a Facebook group which explored the use of cannabis which was enriched with CBD in children with treatment-resistant epilepsy. It was found that sixteen of the 19 parents surveyed reported an improvement in their child's epilepsy. The children surveyed for this paper were all taking cannabis that was purported to contain CBD in a high concentration although the amount of CBD present and the other constituents including THC were not known for many of the cases. Indeed, whilst CBD levels ranged from 0.5 to 28.6 mg/kg/day (in those extracts tested), THC levels as high as 0.8 mg/kg/day were reported.

[0039] Providing children with TRE with a cannabis extract that comprises THC, which has been described as a pro-convulsant (Consroe *et al.*, 1977), at a potentially psychoactive dose of 0.8 mg/kg/day, is a concern and as such there is a need to determine whether CBD is in fact efficacious.

[0040] In November 2013 the company GW Pharmaceuticals made a press release to state that they were intending to treat Dravet Syndrome with CBD as it had received orphan drug designation. A further press release was made in June 2014 which stated promising signals of efficacy in children with treatment-resistant epilepsy, including patients with Dravet syndrome.

[0041] The international patent application WO 2015/193667 describes the use of CBD in treatment resistant epilepsy. Patients included nine with Dravet syndrome out of 27 others.

[0042] The international patent application WO 2015/193668 describes the use of CBD in the treatment of absence seizures. Patients included those with Dravet syndrome in addition to ten other syndromes.

[0043] Maa and Figi (2014) discuss the case for medical marijuana in epilepsy and discuss the positive treatment of a girl Charlotte with Dravet syndrome who experienced frequent bouts of febrile and afebrile status epilepticus as well as tonic, tonic-clonic and myoclonic seizures (generalised seizures). She was given an extract from a cannabis plant dubbed "Charlotte's Web" which according to the suppliers, CW Botanicals, disclose that their extracts are rich in terpenes and contain from 10 to 200 times the amount found in other proprietary plants. In other words the suggestion is that the efficacy is based on a combination of CBD and the terpenes present in their extracts.

[0044] Press *et al*. (3 April 2015), provides an in depth review of the parental reporting of pediatric patients with refractory epilepsy that were given oral cannabis extracts (OCE). Despite it's in depth nature it concludes no studies demonstrate clear efficacy.

[0045] Significantly the document recognizes the effectiveness of an anti-seizure medication may be dependent upon: the drug itself, including CBD, (see Table 3); the epilepsy syndrome type (Table 2); and the seizure type (Table 2).

[0046] Very significantly the document in the discussion recognises caution needs to be taken when reviewing, particularly open label study data, since placebo rates may be high. Indeed it specifically comments that "four recently FDA approved anti-convulsant medications had placebo rates of 31.6%, 26.4%, 20% and 21% respectively" (page 51, left hand column).

[0047] Furthermore the analysis observed a surprising finding namely that "new residents of Colorado (those moving to obtain treatment) were more than three times as likely to report a greater than 50% seizure reduction than families with established care in Colorado" suggestive that studies such as that published in Porter and Jacobson (2013) may be highly flawed.

[0048] The skilled person would infer therefore from Press *et al.* would be that the drug type CBD plus the presence of "other OCE" (such as, other cannabinoids most likely THC and non-cannabinoids such as e.g. terpenes) appears a more interesting combination than CBD alone – responder rate 63% versus 35%.

[0049] That the epilepsy syndrome Lennox-Gastaut appears the most promising target with 89% responder rate versus Dravet (23% responder rate) or Doose (0% responder rate).

[0050] That of the seizure types studied ranged from 44% responder rate for atonic seizures to 17% responder rates in tonic seizures, amongst the seven seizures types reviewed.

[0051] The assessment looked at three distinct groups, namely: the OCE type, Table 3 (four OCE types); the epilepsy syndrome, see for example, page 50 right hand column line 3 (three syndrome types); and the seizure type, see page 51, Table 2 (seven seizure types).

[0052] In all this provides the reader with information on 84 different alternative combinations.

[0053] The problem facing the skilled practitioner looking at cannabis medicines in the field of epilepsy where many patients are refractory to existing medications is to select the appropriate cannabinoid and its form targeted to a given seizure type in a given patient group.

[0054] Perhaps therefore it is not surprising that in the Cochrane report (Gloss and Vickrey) published March 2014 undertook a full review on the efficacy of cannabinoids in the treatment of epilepsy concluded "no reliable conclusions can be drawn at present regarding the efficacy of cannabinoids as a treatment for epilepsy."

[0055] Surprisingly the applicant has shown that CBD is particularly effective in the treatment of focal seizures in Dravet syndrome patients, particularly children and more particularly those which are resistant to existing treatments.

BRIEF SUMMARY OF THE DISCLOSURE

[0056] In accordance with a first aspect of the present invention there is provided Cannabidiol (CBD) for use in the treatment of focal seizures in Dravet Syndrome.

[0057] In one embodiment the focal seizures are focal seizures with impairment.

[0058] Preferably the Dravet Syndrome is treatment-resistant.

[0059] In a further embodiment the CBD is for use in combination with one or more concomitant anti-epileptic drugs (AED).

[0060] In a further embodiment the CBD is present as a highly purified extract of cannabis which comprises at least 98% (w/w) CBD. Preferably the extract comprises less than 0.15% THC. More preferably the extract further comprises up to 1% CBDV.

[0061] In an alternative embodiment the CBD is present as a synthetic compound.

[0062] In a further embodiment of the invention the one or more AED is selected from the group consisting of: carbamezapine, clobazam, clonazepam, clonidine, clorazepate, desmethylclobazam, diazepam, ethosuximide, felbamate, ketogenic diet, lacosamide,

lamotrigine, levetiracetam, lorazepam, midazolam, N-desmethylclobazam, nordiazepam, oxycarbamezapine, perampanel, phenobarbital, phenytoin, pregabalin, rufinamide, stiripentol, topiramate, trazodone, vagus nerve stimulation, valproic acid, vigabatrin, and zonisamide.

[0063] Preferably the number of different anti-epileptic drugs that are used in combination with the CBD is reduced. Alternatively the dose of anti-epileptic drugs that are used in combination with the CBD is reduced.

[0064] There are many side effects associated with the commonly used AED which include dizziness, blurred vision, nausea, respiratory system depression, tiredness, headaches, and other motor side effects on the central nervous system. These side effects are particularly common as higher doses or combinations of numerous AED are used. As such there is a need for an alternative medication that is able to reduce the numbers of seizures whilst at the same time exhibiting a safe side effect profile.

[0065] Preferably the dose of CBD is greater than 5 mg/kg/day. Thus for a 15 kg patient a dose of greater than 75mg of CBD per day would be provided. Doses greater than 5mg/kg/day such as greater than 10/mg/kg/day, greater than 15 mg/kg/day, greater than 20mg/kg/day and greater than 25 mg/kg/day are also envisaged to be effective.

[0066] In accordance with a second aspect of the present invention there is provided a method of treating focal seizures in Dravet Syndrome comprising administering cannabidiol (CBD) to a subject.

[0067] Preferably the subject is a human.

[0068] In accordance with a third aspect of the present invention there is provided a composition for use in the treatment of epilepsy characterised by focal seizures in Dravet syndrome comprising cannabidiol (CBD), a solvent, a co-solvent, a sweetener, and a flavouring.

[0069] Preferably the solvent is sesame oil, the co-solvent is ethanol, the sweetener is sucralose, the flavouring is strawberry flavour and the CBD is present at a concentration of between 25/mg/ml and 100 mg/ml, namely 50mg/ml and 75 mg/ml.

[0070] More preferably the composition comprises cannabidiol (CBD) at a concentration of between 25 to 100 mg/ml, ethanol at a concentration of 79 mg/ml, sucralose at a concentration of 0.5 mg/ml, strawberry flavouring at a concentration of 0.2 mg/ml and sesame oil q.s. to 1.0ml.

[0071] It is envisaged that the composition be administered as an oral liquid solution. Other modes of administration including solids, semi-solids, gels, sprays, aerosols, inhalers, vaporisers, enemas and suppositories are alternative administration forms. Such medicaments

could be administered via the oral, buccal, sublingual, respiratory, nasal and distal rectum route.

DEFINITIONS

[0072] Definitions of some of the terms used to describe the invention are detailed below:

[0073] The cannabinoids described in the present application are listed below along with their standard abbreviations.

Table 4. Cannabinoids and their abbreviations

CBD	Cannabidiol	
CBDA	Cannabidiolic acid	
CBDV	Cannabidivarin	
CBDVA	Cannabidivarinic acid	
THC	Tetrahydrocannabinol	

[0074] The table above is not exhaustive and merely details the cannabinoids which are identified in the present application for reference. So far over 60 different cannabinoids have been identified and these cannabinoids can be split into different groups as follows: Phytocannabinoids; Endocannabinoids and Synthetic cannabinoids (which may be novel cannabinoids or synthetically produced phytocannabinoids or endocannabinoids).

[0075] "Phytocannabinoids" are cannabinoids that originate from nature and can be found in the cannabis plant. The phytocannabinoids can be isolated from plants to produce a highly purified extract or can be reproduced synthetically.

[0076] "Highly purified cannabinoid extracts" are defined as cannabinoids that have been extracted from the cannabis plant and purified to the extent that other cannabinoids and non-cannabinoid components that are co-extracted with the cannabinoids have been substantially removed, such that the highly purified cannabinoid is greater than or equal to 98% (w/w) pure.

[0077] "Synthetic cannabinoids" are compounds that have a cannabinoid or cannabinoid-like structure and are manufactured using chemical means rather than by the plant.

[0078] Phytocannabinoids can be obtained as either the neutral (decarboxylated form) or the carboxylic acid form depending on the method used to extract the cannabinoids. For example it is known that heating the carboxylic acid form will cause most of the carboxylic acid form to decarboxylate into the neutral form.

[0079] "Treatment-resistant epilepsy" (TRE) or "intractable epilepsy" is defined as per the ILAE guidance of 2009 as epilepsy that is not adequately controlled by trials of one or more AED.

[0080] "Childhood epilepsy" refers to the many different syndromes and genetic mutations that can occur to cause epilepsy in childhood. Examples of some of these are as follows: Dravet Syndrome; Myoclonic-Absence Epilepsy; Lennox-Gastaut syndrome; Generalized Epilepsy of unknown origin; CDKL5 mutation; Aicardi syndrome; bilateral polymicrogyria; Dup15q; SNAP25; and febrile infection related epilepsy syndrome (FIRES); benign rolandic epilepsy; juvenile myoclonic epilepsy; infantile spasm (West syndrome); and Landau-Kleffner syndrome. The list above is non-exhaustive as many different childhood epilepsies exist.

[0081] "Focal Seizures" are defined as seizures which originate within networks limited to only one hemisphere. What happens during the seizure depends on where in the brain the seizure happens and what that part of the brain normally does.

[0082] "Focal seizure where awareness / consciousness are impaired" has replaced the term "complex partial seizure". These seizures usually start in a small area of the temporal lobe or

frontal lobe of the brain and involve other areas of the brain within the same hemisphere that affect alertness and awareness. Most subjects experience automatisms during a focal seizure with impaired consciousness.

[0083] "Mixed seizures" are defined as the existence of both generalised and focal seizures in the same patient.

[0084] The terms "50% responder" and "50% reduction in seizure" are both terms used in clinical studies. In the present application the terms define the percentage of subjects that experienced a greater than or equal to 50% reduction in the number of seizures during treatment with CBD in comparison to the number experienced during the baseline period before the CBD was administered.

DETAILED DESCRIPTION

PREPARATION OF HIGHLY PURIFIED CBD EXTRACT

[0085] The following describes the production of the highly-purified (>98% w/w) cannabidiol extract which has a known and constant composition which was used for the expanded access trials described in the Examples below.

[0086] In summary the drug substance used in the trials is a liquid carbon dioxide extract of high-CBD containing chemotypes of *Cannabis sativa* L. which had been further purified by a solvent crystallization method to yield CBD. The crystallisation process specifically removes other cannabinoids and plant components to yield greater than 98% CBD.

[0087] The *Cannabis sativa* L. plants are grown, harvested, and processed to produce a botanical extract (intermediate) and then purified by crystallization to yield the CBD (drug substance).

[0088] The plant starting material is referred to as Botanical Raw Material (BRM); the botanical extract is the intermediate; and the active pharmaceutical ingredient (API) is CBD, the drug substance.

[0089] Both the botanical starting material and the botanical extract are controlled by specifications. The drug substance specification is described in Table 1 below.

Table 5. CBD Specification

Test	Test Method	Limits
Appearance	Visual	Off-white / pale yellow crystals
Identification A	HPLC-UV	Retention time of major peak corresponds to certified CBD

Test	Test Method	Limits
		Reference Standard
Identification B	GC-FID/MS	Retention time and mass spectrum of major peak corresponds to certified CBD Reference Standard
Identification C	FT-IR	Conforms to reference spectrum for certified CBD Reference Standard
Identification D	Melting Point	65 - 67°C
Identification E	Specific Optical Rotation	Conforms with certified CBD Reference Standard; -110° to -140° (in 95% ethanol)
Total Purity	Calculation	≥ 98.0%
Chromatographic Purity 1	HPLC-UV	≥ 98.0%
Chromatographic Purity 2	GC-FID/MS	≥ 98.0 %
Other Cannabinoids: - CBDA - CBDV - Δ^9 THC - CBD-C4	HPLC-UV	 NMT 0.15% w/w NMT 1.0% w/w NMT 0.15% w/w NMT 0.5% w/w
Residual Solvents: - Alkane - Ethanol	GC	 NMT 0.5% w/w NMT 0.5% w/w
Residual Water	Karl Fischer	NMT 1.0% w/w

NMT- Not more than

[0090] The purity of the CBD drug substance achieved is greater than 98%. The other cannabinoids which may occur in the extract are: CBDA, CBDV, CBD-C4 and THC.

[0091] Distinct chemotypes of *Cannabis sativa* L. plant have been produced to maximize the output of the specific chemical constituents, the cannabinoids. One type of plant produces predominantly CBD. Only the (–)-trans isomer occurs naturally. Furthermore during purification the stereochemistry of CBD is not affected.

Production of the Intermediate

[0092] An overview of the steps to produce a botanical extract, the intermediate, are as follows:

1. Growing
2. Decarboxylation
3. Extraction No.1 - using liquid CO_2
4. Extraction No.2 - 'winterization' using ethanol
5. Filtration
6. Evaporation

[0093] High CBD chemovars were grown, harvested and dried and stored in a dry room until required. The botanical raw material (BRM) was finely chopped using an Apex mill fitted with a 1mm screen. The milled BRM was stored in a freezer for up to 3 months prior to extraction.

[0094] Decarboxylation of CBDA to CBD was carried out using a large Heraeus tray oven. The decarboxylation batch size in the Heraeus is approximately 15 Kg. Trays were placed in the oven and heated to 105ºC; the BRM took 96.25 minutes to reach 105 ºC. Held at 105ºC for 15 Minutes. Oven then set to 150ºC.; the BRM took 75.7 minutes to reach 150ºC; BRM held at 150ºC for 130 Minutes. Total time in the oven was 380 Minutes, including 45 minutes cooling and 15 Minutes venting.

[0095] Extraction No 1 was performed using liquid CO_2 at 60 bar / 10°C to produce botanical drug substance (BDS).

[0096] The crude CBD BDS was winterised in Extraction No 2 under standard conditions (2 volumes of ethanol at minus 20°C for around 50 hours). The precipitated waxes were removed by filtration and the solvent evaporated using the rotary evaporator (water bath up to 60°C) to yield the BDS, which was then used for crystallisation to produce the test material..

Production of the Drug Substance

[0097] The manufacturing steps to produce the drug substance from the intermediate botanical extract are as follows:

1. Crystallization using C5-C12 straight chain or branched alkane
2. Filtration
3. Optional recrystallization from C5-C12 straight chain or branched alkane
4. Vacuum drying

[0098] Intermediate botanical extract (12kg) produced using the methodology above was dispersed in C5-C12 straight chain or branched alkane (9000 ml, 0.75 vols) in a 30 litre stainless steel vessel.

[0099] The mixture was manually agitated to break up any lumps and the sealed container then placed in a freezer for approximately 48 hours.

[00100] The crystals were isolated by vacuum filtration, washed with aliquots of cold C5-C12 straight chain or branched alkane (total 12000 ml), and dried under a vacuum of < 10mb at a temperature of 60°C until dry before submitting the drug substance for analysis.

[00101] The dried product was stored in a freezer at minus 20°C in a pharmaceutical grade stainless steel container, with FDA food grade approved silicone seal and clamps.

Production of the Drug Product

[00102] The drug product is presented as an oral solution. The oral solution presentation contains 25mg/ml or 100mg/ml CBD, with the excipients sesame oil, ethanol, sucralose and flavouring. Two product strengths are available to allow dose titration across a wide dose range.

[00103] The 25 mg/ml solution is appropriate at lower doses and the 100 mg/ml solution at higher doses.

[00104] The drug product formulation is as described in Table 6 below:

Table 6: Drug Product specification

Component	Qualitative Composition	Function	Reference to Quality Standard
Cannabidiol (CBD)	25 mg/ml or 100 mg/ml	Active	In-house
Anhydrous ethanol	79.0 mg/ml*	Excipient	Ph.Eur.
Sucralose	0.5 mg/ml	Sweetener	In-house
Strawberry flavouring	0.2 mg/ml	Flavouring	In-house
Sesame oil	q.s to 1.0 ml	Excipient	Ph.Eur.

[00105] The drug substance, CBD is insoluble in water. Sesame oil was selected as an excipient to solubilize the drug substance.

[00106] A sweetener and fruit flavouring are required to improve palatability of the sesame oil solution.

[00107] Ethanol was required to solubilize the sweetener and the flavouring.

[00108] The composition can be substantially equivalent, by which is meant the functional ingredients can vary from the qualitative composition specified in Table 6 by an amount of up to 10%.

[00109] Example 1 below describes the use of a highly purified cannabis extract comprising cannabidiol (CBD). Cannabidiol is the most abundant non-psychoactive cannabinoid in the selected chemovar. Previous studies in animals have demonstrated that CBD has anticonvulsant efficacy in multiple species and models.

[00110] Example 1 describes data produced in an expanded access treatment program in children with TRE.

EXAMPLE 1: EFFICACY OF CANNABIDIOL REDUCING FOCAL SEIZURES IN CHILDREN AND YOUNG ADULTS WITH INTRACTABLE EPILEPSY

Materials and Methods

[00111] Of 137 children and young adults with severe, childhood onset treatment-resistant epilepsy (TRE), fifty-one suffered from epilepsy that was characterised by focal seizures. These subjects were tested with a highly purified extract of cannabidiol (CBD) obtained from a cannabis plant. All subjects presented with focal type seizures, often in addition to generalised seizures. The participants in the study were part of an expanded access compassionate use program for CBD.

[00112] The epileptic syndromes that these patients suffered from were as follows: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKL5; Neuronal ceroid lipofuscinoses (NCL); febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities.

[00113] Other seizure types experienced by these patients included: tonic, clonic, tonic-clonic, myoclonic, atonic, absence, myoclonic-absence, focal seizures without impairment, focal seizures with impairment and focal seizures evolving to bilateral convulsive seizures.

[00114] All patients entered a baseline period of 4 weeks when parents/caregivers kept prospective seizure diaries, noting all countable seizure types.

[00115] The patients then received a highly purified CBD extract (greater than 98% CBD w/w) in sesame oil, of known and constant composition, at a dose of 5 mg/kg/day in addition to their baseline anti-epileptic drug (AED) regimen.

[00116] The daily dose was gradually increased by 2 to 5mg/kg increments until intolerance occurred or a maximum dose of 25 mg/kg/day was achieved.

[00117] Patients were seen at regular intervals of 2-4 weeks. Laboratory testing for hematologic, liver, kidney function and concomitant AED levels was performed at baseline, and after every 4 weeks of CBD therapy.

[00118] The patients on the study were all taking at least one concomitant AED. These included: carbamezapine, clobazam, clonazepam, clonidine, clorazepate, desmethylclobazam, diazepam, ethosuximide, felbamate, ketogenic diet, lacosamide, lamotrigine, levetiracetam, lorazepam, midazolam, N-desmethylclobazam, nordiazepam, oxycarbamezapine, perampanel, phenobarbital, phenytoin, pregabalin, rufinamide, stiripentol, topiramate, trazodone, vagus nerve stimulation, valproic acid, vigabatrin, and zonisamide.

Results

[00119] The 51 children and young adult patients all of whom suffered from focal seizures received treatment with CBD who received treatment for at least 12 weeks.

[00120] A summary of the 50% responders, based on 12 weeks of treatment are summarized in Table 7 below.

Table 7. Summary of 50% responders after 12 weeks of treatment for focal seizures

	Focal seizures (n=51)	**Total seizures (n=137)**
> 50% reduction in seizures	63% (n=32)	46% (n=63)
< 50% reduction in seizures	37% (n=19)	54% (n=74)

[00121] Table 7 shows that after 3 months of therapy, a remarkable 63% of patients had an equal to or greater than >50% reduction in focal seizures, these data infer that the CBD is very effective at reducing this type of seizure.

Conclusions

[00122] These data indicate that CBD significantly reduces the number of focal seizures in a high proportion of patients that do not respond well to existing AED.

[00123] It was surprising that in this group of patients which are treatment-resistant such a high number were able to gain an effect. The fact that nearly two thirds of the patients (63%) benefitted from at least a fifty percent reduction in the number of focal seizures that they suffered from was remarkable.

EXAMPLE 2: EFFICACY OF CANNABIDIOL REDUCING FOCAL SEIZURES WITH IMPAIRMENT IN CHILDREN AND YOUNG ADULTS WITH INTRACTABLE EPILEPSY

Materials and Methods

[00124] Of 137 children and young adults with severe, childhood onset treatment-resistant epilepsy (TRE), thirty-seven suffered from epilepsy that was characterised by focal seizures

with impairment. These subjects were tested with a highly purified extract of cannabidiol (CBD) obtained from a cannabis plant. All subjects presented with focal seizures with impairment, often in addition to other generalised and / or focal seizures. The participants in the study were part of an expanded access compassionate use program for CBD.

[00125] The epileptic syndromes that these patients suffered from were as follows: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKL5; febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities.

[00126] All patients entered a baseline period of 4 weeks when parents/caregivers kept prospective seizure diaries, noting all countable seizure types.

[00127] The patients then received a highly purified CBD extract (greater than 98% CBD w/w) in sesame oil, of known and constant composition, at a dose of 5 mg/kg/day in addition to their baseline anti-epileptic drug (AED) regimen.

[00128] The daily dose was gradually increased by 2 to 5mg/kg increments until intolerance occurred or a maximum dose of 25 mg/kg/day was achieved.

[00129] Patients were seen at regular intervals of 2-4 weeks. Laboratory testing for hematologic, liver, kidney function and concomitant AED levels was performed at baseline, and after every 4 weeks of CBD therapy.

[00130] The patients on the study were all taking at least one concomitant AED. These included: carbamezapine, clobazam, clonazepam, clorazepate, desmethylclobazam, diazepam, ethosuximide, felbamate, ketogenic diet, lacosamide, lamotrigine, levetiracetam, lorazepam, midazolam, N-desmethylclobazam, nordiazepam, oxycarbamezapine, perampanel, phenobarbital, phenytoin, pregabalin, rufinamide, topiramate, vagus nerve stimulation, valproic acid, vigabatrin, and zonisamide.

Results

[00131] The 37 children and young adult patients all of whom suffered from focal seizures with impairment received treatment with CBD who received treatment for at least 12 weeks.

[00132] A summary of the 50% responders, based on 12 weeks of treatment are summarized in Table 8 below.

Table 8. Summary of 50% responders after 12 weeks of treatment for focal seizures with impairment

	Focal Seizures with Impairment (n=37)	**Total seizures (n=137)**
> 50% reduction in seizures	65% (n=24)	46% (n=63)

< 50% reduction in seizures	35% (n=13)	54% (n=74)

[00133] Table 8 shows that after 3 months of therapy, a remarkable 65% of patients had an equal to or greater than >50% reduction in focal seizures with impairment, these data infer that the CBD is very effective at reducing this type of seizure.

[00134] Furthermore when these data are compared to the other sub-types of focal seizure, namely focal seizure without impairment and focal seizures leading to secondary generalisation it can clearly be seen that CBD was able to selectively reduce the occurrence of focal seizures with impairment. Table 9 below details these findings.

Table 9. Summary of 50% responders after 12 weeks of treatment for all focal seizure types

	Focal Seizures with Impairment (n=37)	**Focal Seizures without Impairment (n=6)**	**Focal Seizures Leading to Secondary Generalised (n=15)**	**Total Focal seizures (n=51)**
> 50% reduction in seizures	65% (n=24)	50% (n=3)	47% (n=7)	63% (n=32)
< 50% reduction in seizures	35% (n=13)	50% (n=3)	53% (n=8)	37% (n=19)

Conclusions

[00135] These data indicate that CBD significantly reduces the number of focal seizures with impairment in a selective manner.

[00136] It was surprising that in this group of patients which are treatment-resistant such a high number were able to gain an effect. The fact that over two thirds of the patients (65%) benefitted from at least a fifty percent reduction in the number of focal seizures with impairment that they suffered from was remarkable.

References:

Ames FR and Cridland S (1986). "Anticonvulsant effects of cannabidiol." S Afr Med J 69:14.

Consroe P, Martin P, Eisenstein D. (1977). "Anticonvulsant drug antagonism of delta-9-tetrahydrocannabinol induced seizures in rabbits." Res Commun Chem Pathol Pharmacol. 16:1-13

Consroe P, Benedicto MA, Leite JR, Carlini EA, Mechoulam R. (1982). "Effects of cannabidiol on behavioural seizures caused by convulsant drugs or current in mice." Eur J Pharmaco. 83: 293-8

Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimental C, Gagliardi R *et al.* (1980). "Chronic administration of cannabidiol to healthy volunteers and epileptic patient." Pharmacology. 21:175-85

Dravet C. The core Dravet syndrome phenotype. Epilepsia. 2011 Apr;52 Suppl 2:3-9.

Eadie, MJ (December 2012). "Shortcomings in the current treatment of epilepsy." *Expert Review of Neurotherapeutics* 12 (12): 1419–27.

Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Hauser WA, Mathern G, Moshé SL, Perucca E, Wiebe S, French J. (2009) "Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies." *Epilepsia.*

Mechoulam R and Carlini EA (1978). "Toward drugs derived from cannabis." Die naturwissenschaften 65:174-9.

Porter BE, Jacobson C (December 2013). "Report of a parent survey of cannabidiol-enriched cannabis use in paediatric treatment resistant epilepsy" Epilepsy Behaviour. 29(3) 574-7

Thurman, DJ; Beghi, E; Begley, CE; Berg, AT; Buchhalter, JR; Ding, D; Hesdorffer, DC; Hauser, WA; Kazis, L; Kobau, R; Kroner, B; Labiner, D; Liow, K; Logroscino, G; Medina, MT; Newton, CR; Parko, K; Paschal, A; Preux, PM; Sander, JW; Selassie, A; Theodore, W; Tomson, T; Wiebe, S; ILAE Commission on, Epidemiology (September 2011). "Standards for epidemiologic studies and surveillance of epilepsy." *Epilepsia*. 52 Suppl 7: 2–26

CLAIMS

1. Cannabidiol (CBD) for use in the treatment of focal seizures in Dravet Syndrome.

2. CBD for use according to claim 1, wherein the focal seizures are focal seizures with impairment.

3. Cannabidiol (CBD) for use according to claim 1 or claim 2, wherein the Dravet Syndrome is treatment-resistant.

4. CBD for use according to any of the preceding claims, wherein the CBD is for use in combination with one or more concomitant anti-epileptic drugs (AED).

5. CBD for use according to any of the preceding claims, wherein the CBD is present as a highly purified extract of cannabis which comprises at least 98% (w/w) CBD.

6. CBD for use according to claim 5 wherein the extract comprises less than 0.15% THC.

7. CBD for use according to claim 5 or 6 wherein the extract further comprises up to 1% CBDV.

8. CBD for use according to any of the preceding claims, where in the CBD is present as a synthetic compound.

9. CBD for use according to claim 4, wherein the one or more AED is selected from the group consisting of: carbamezapine, clobazam, clonazepam, clonidine, clorazepate, desmethylclobazam, diazepam, ethosuximide, felbamate, ketogenic diet, lacosamide, lamotrigine, levetiracetam, lorazepam, midazolam, N-desmethylclobazam, nordiazepam, oxycarbamezapine, perampanel, phenobarbital, phenytoin, pregabalin, rufinamide, stiripentol, topiramate, trazodone, vagus nerve stimulation, valproic acid, vigabatrin, and zonisamide.

10. CBD for use according to any of the preceding claims, wherein the number of different anti-epileptic drugs that are used in combination with the CBD is reduced.

11. CBD for use according to any of the preceding claims, wherein the dose of anti-epileptic drugs that are used in combination with the CBD is reduced.

12. CBD for use according to any of the preceding claims, wherein the dose of CBD is greater than 5 mg/kg/day.

13. A method of treating focal seizures in Dravet Syndrome comprising administering cannabidiol (CBD) to a subject.

14. A composition for use in the treatment of epilepsy characterised by focal seizures in Dravet syndrome comprising cannabidiol (CBD), a solvent, a co-solvent, a sweetener, and a flavouring.

15. A composition according to claim 14, wherein the solvent is sesame oil.

16. A composition according to claim 14, wherein the co-solvent is ethanol.

17. A composition according to claim 14, wherein the sweetener is sucralose.

18. A composition according to claim 14, wherein the flavouring is strawberry flavour.

19. A composition according to claim 14, wherein the CBD is present at a concentration of between 25/mg/ml and 100 mg/ml.

20. A composition according to any of claims 14 to 19, which comprises cannabidiol (CBD) at a concentration of between 25 to 100 mg/ml, ethanol at a concentration of 79 mg/ml, sucralose at a concentration of 0.5 mg/ml, strawberry flavouring at a concentration of 0.2 mg/ml and sesame q.s. to 1.0ml.

Figure 1. ILAE Proposal for Revised Terminology for Organisation of Seizures and Epilepsies 2010



INTERNATIONAL SEARCH REPORT

International application No
PCT/GB2016/051792

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K45/06 A61K31/352 A61K36/185 A61P25/08
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal, BIOSIS, CHEM ABS Data, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EDWARD MAA ET AL: "The case for medical marijuana in epilepsy", EPILEPSIA, vol. 55, no. 6, 1 June 2014 (2014-06-01), pages 783-786, XP055205357, ISSN: 0013-9580, DOI: 10.1111/epi.12610 the whole document ----- -/--	1-6,9-13

[X] Further documents are listed in the continuation of Box C.

[X] See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
23 August 2016	31/08/2016

Name and mailing address of the ISA/	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Ansaldo, M

INTERNATIONAL SEARCH REPORT

International application No
PCT/GB2016/051792

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PORTER BRENDA E ET AL: "Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy", EPILEPSY AND BEHAVIOR, vol. 29, no. 3, 30 August 2013 (2013-08-30), pages 574-577, XP028775189, ISSN: 1525-5050, DOI: 10.1016/J.YEBEH.2013.08.037 abstract; table 1	1-3,5,6, 8,12,13
X	Anonymous: "GWPharma - GW Pharmaceuticals Provides Update on Orphan Program in Childhood Epilepsy for Epidiolex", , 14 November 2013 (2013-11-14), XP055205615, Retrieved from the Internet: URL:http://www.gwpharm.com/GW%20Pharmaceuticals%20Provides%20Update%20on%20Orphan%20Program%20in%20Childhood%20Epilepsy%20for%20Epidiolex.aspx [retrieved on 2015-07-30] the whole document	1-3,5,6, 13-20
X	Anonymous: "GWPharma - GW Pharmaceuticals Announces Epidiolex Receives Fast Track Designation from FDA for the Treatment of Dravet Syndrome", , 6 June 2014 (2014-06-06), XP055205380, Retrieved from the Internet: URL:http://www.gwpharm.com/GW%20Pharmaceuticals%20Announces%20Epidiolex%20Receives%20Fast%20Track%20Designation%20from%20FDA%20for%20the%20Treatment%20of%20Dravet%20Syndrome.aspx [retrieved on 2015-07-29] the whole document	1-3,5,6, 13-20
X	WO 2012/093255 A1 (GW PHARMA LTD [GB]; OTSUKA PHARMA CO LTD [JP]; WHALLEY BENJAMIN [GB];) 12 July 2012 (2012-07-12) abstract	4,9-11
X,P	WO 2015/193668 A1 (GW PHARMA LTD [GB]) 23 December 2015 (2015-12-23) claims 7, 11, 13,20-26; example 1	1-20
X,P	& WO 2015/193667 A1 (GW PHARMA LTD [GB]) 23 December 2015 (2015-12-23) claim 4; example 2	1-20
X,P	WO 2016/059404 A1 (GW PHARMA LTD [GB]) 21 April 2016 (2016-04-21) claims 3, 6, 9, 11-22	1-20

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB2016/051792

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☒ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-20

   composition and treatment of focal seizures in Dravet Syndrome

1.1. claims: 1-13

   use of CBD for the treatment of focal seizures in Dravet Syndrome

1.2. claims: 14-20

   provision of a CBD composition

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/GB2016/051792

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2012093255 A1	12-07-2012	AR 084559 A1	22-05-2013
		CA 2822907 A1	12-07-2012
		CN 103391775 A	13-11-2013
		CO 6731122 A2	15-08-2013
		EP 2661263 A1	13-11-2013
		GB 2487712 A	08-08-2012
		JP 2014501271 A	20-01-2014
		KR 20130132972 A	05-12-2013
		NZ 613307 A	27-11-2015
		RU 2013136378 A	10-02-2015
		SG 191835 A1	30-08-2013
		TW 201306826 A	16-02-2013
		US 2013296398 A1	07-11-2013
		WO 2012093255 A1	12-07-2012
		ZA 201305508 B	30-04-2014
WO 2015193668 A1	23-12-2015	GB 2530001 A	16-03-2016
		GB 2531093 A	13-04-2016
		US 2015359755 A1	17-12-2015
		US 2015359756 A1	17-12-2015
		WO 2015193667 A1	23-12-2015
		WO 2015193668 A1	23-12-2015
WO 2016059404 A1	21-04-2016	GB 2531278 A	20-04-2016
		WO 2016059404 A1	21-04-2016

摘要

本發明涉及大麻二酚（CBD）在治療局竈性癲癇發作中的用途。在一個實施方案中，罹患局竈性癲癇發作的患者是兒童和年輕的成年人。CBD 表現出與其他癲癇發作類型相比，在降低罹患包括以下的病因的患者中特別有效：倫諾克斯-加斯圖特綜合征；結節性硬化症；Dravet 綜合征；CDKL5； 神經元蠟樣脂褐質沈積症（NCL）；熱性感染相關性癲癇綜合征（FIRES）；艾卡爾迪綜合征和腦部異常。顯著地，CBD 另外在局竈性癲癇發作的一種亞型伴有損傷的局竈性癲癇發作中極為有效。